Literature DB >> 21228419

Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders.

R Kaul1, T B Ball, T Hirbod.   

Abstract

The sexual transmission of HIV is very inefficient, presumably because mucosal immune defences prevent infection after most exposures. Since numerous genital immune factors have antiviral effects in vitro, their elucidation might greatly inform the microbicide and HIV prevention fields, particularly in the context of HIV-exposed but persistently seronegative (ESN) individuals. However, several important confounders must be considered in such research. First, sound epidemiological criteria are needed to define individuals as ESN. Then, since high-risk sexual activity is commonly one of these criteria, its potential impact on genital immunology must be carefully considered, both the direct effects of sex and the secondary immune effects of genital co-infections. This means that it may be very difficult to determine whether differences in genital immunology between ESN and control groups are responsible for HIV protection, or are a consequence of high-risk sexual activity. To overcome this confounding, the demographics and epidemiology of ESN cohorts must be described very carefully, thorough co-infection diagnostics must be performed and, if possible, prospective studies with an endpoint of HIV acquisition should be performed to define the direction of causality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228419     DOI: 10.1136/sti.2009.040931

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  6 in total

1.  Genital inflammation and the risk of HIV acquisition in women.

Authors:  Lindi Masson; Jo-Ann S Passmore; Lenine J Liebenberg; Lise Werner; Cheryl Baxter; Kelly B Arnold; Carolyn Williamson; Francesca Little; Leila E Mansoor; Vivek Naranbhai; Douglas A Lauffenburger; Katharina Ronacher; Gerhard Walzl; Nigel J Garrett; Brent L Williams; Mara Couto-Rodriguez; Mady Hornig; W Ian Lipkin; Anneke Grobler; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

Review 2.  Genital inflammation, immune activation and risk of sexual HIV acquisition.

Authors:  Jo-Ann S Passmore; Heather B Jaspan; Lindi Masson
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

3.  Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.

Authors:  Gloria Omosa-Manyonyi; Harriet Park; Gaudensia Mutua; Bashir Farah; Philip J Bergin; Dagna Laufer; Jennifer Lehrman; Kundai Chinyenze; Burc Barin; Pat Fast; Jill Gilmour; Omu Anzala
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

4.  HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men.

Authors:  Taha Hirbod; Xiangrong Kong; Godgrey Kigozi; Anthony Ndyanabo; David Serwadda; Jessica L Prodger; Aaron A Tobian; Fred Nalugoda; Maria J Wawer; Kamnoosh Shahabi; Olga L Rojas; Jennifer L Gommerman; Kristina Broliden; Rupert Kaul; Ronald H Gray
Journal:  PLoS Pathog       Date:  2014-10-02       Impact factor: 6.823

5.  Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya.

Authors:  Duncan Chege; Yijie Chai; Sanja Huibner; Taylor Kain; Charles Wachihi; Makubo Kimani; Samson Barasa; Lyle R McKinnon; Festus K Muriuki; Anthony Kariri; Walter Jaoko; Omu Anzala; Joshua Kimani; T Blake Ball; Francis A Plummer; Rupert Kaul
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

6.  Feasibility and safety of cervical biopsy sampling for mucosal immune studies in female sex workers from Nairobi, Kenya.

Authors:  Klara Hasselrot; Juliana Cheruiyot; Joshua Kimani; Terry B Ball; Rupert Kaul; Taha Hirbod
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.